NRX Pharmaceuticals Signs 12-Part Media Partnership with New to The Street for National Broadcast Series

Reuters

06 Jun

NRX Pharmaceuticals Signs 12-Part Media Partnership with New to The Street for National Broadcast Series

NRX Pharmaceuticals Inc. has signed a 12-part media partnership with New to The Street, a leading multi-platform financial news show, to enhance its media presence. This collaboration will feature monthly televised interviews with NRx CEO Dr. Jonathan Javitt, focusing on the company's advancements in therapies for suicidal depression, PTSD, and chronic pain. The campaign will include earned media placements on major networks like ABC, NBC, and CBS, along with nationally aired TV commercials and prominent billboard exposure in Times Square and the NYC Financial District. This initiative aims to highlight NRX's innovative work in neuroscience and public health to a global audience, with programming set to reach over 245 million homes weekly across the U.S. and Middle East.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036120) on June 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2541500341"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541500341\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2541500341?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-06 03:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541500341","market":"nz","top_or_hot":-1,"title":"NRX Pharmaceuticals Signs 12-Part Media Partnership with New to The Street for National Broadcast Series","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NRX Pharmaceuticals Signs 12-Part Media Partnership with New to The Street for National Broadcast Series\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NRXP\">NRX Pharmaceuticals Inc.</a> has signed a 12-part media partnership with New to The Street, a leading multi-platform financial news show, to enhance its media presence. This collaboration will feature monthly televised interviews with NRx CEO Dr. Jonathan Javitt, focusing on the company's advancements in therapies for suicidal depression, PTSD, and chronic pain. The campaign will include earned media placements on major networks like ABC, NBC, and CBS, along with nationally aired TV commercials and prominent billboard exposure in Times Square and the NYC Financial District. This initiative aims to highlight NRX's innovative work in neuroscience and public health to a global audience, with programming set to reach over 245 million homes weekly across the U.S. and Middle East.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036120) on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NRX Pharmaceuticals Signs 12-Part Media Partnership with New to The Street for National Broadcast Series</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNRX Pharmaceuticals Signs 12-Part Media Partnership with New to The Street for National Broadcast Series\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-06 03:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NRX Pharmaceuticals Signs 12-Part Media Partnership with New to The Street for National Broadcast Series\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NRXP\">NRX Pharmaceuticals Inc.</a> has signed a 12-part media partnership with New to The Street, a leading multi-platform financial news show, to enhance its media presence. This collaboration will feature monthly televised interviews with NRx CEO Dr. Jonathan Javitt, focusing on the company's advancements in therapies for suicidal depression, PTSD, and chronic pain. The campaign will include earned media placements on major networks like ABC, NBC, and CBS, along with nationally aired TV commercials and prominent billboard exposure in Times Square and the NYC Financial District. This initiative aims to highlight NRX's innovative work in neuroscience and public health to a global audience, with programming set to reach over 245 million homes weekly across the U.S. and Middle East.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036120) on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRXP","symbol_name":"NRX Pharmaceuticals Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL2JZgg2:1","article_id":"2541500341","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541500341","pubTimestamp":1749153092,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NRX Pharmaceuticals Inc. has signed a 12-part media partnership with New to The Street, a leading multi-platform financial news show, to enhance its media presence. This collaboration will feature monthly televised interviews with NRx CEO Dr. Jonathan Javitt, focusing on the company's advancements in therapies for suicidal depression, PTSD, and chronic pain. The campaign will include earned media placements on major networks like ABC, NBC, and CBS, along with nationally aired TV commercials and prominent billboard exposure in Times Square and the NYC Financial District. This initiative aims to highlight NRX's innovative work in neuroscience and public health to a global audience, with programming set to reach over 245 million homes weekly across the U.S. and Middle East.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRXP":"NRX Pharmaceuticals Inc.","BK4007":"制药"},"translate_title":"NRX Pharmaceuticals与New to The Street签署12集媒体合作伙伴关系，制作全国广播系列节目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRXP":0.9},"content_text":"NRX Pharmaceuticals Signs 12-Part Media Partnership with New to The Street for National Broadcast Series\n    \n\nNRX Pharmaceuticals Inc. has signed a 12-part media partnership with New to The Street, a leading multi-platform financial news show, to enhance its media presence. This collaboration will feature monthly televised interviews with NRx CEO Dr. Jonathan Javitt, focusing on the company's advancements in therapies for suicidal depression, PTSD, and chronic pain. The campaign will include earned media placements on major networks like ABC, NBC, and CBS, along with nationally aired TV commercials and prominent billboard exposure in Times Square and the NYC Financial District. This initiative aims to highlight NRX's innovative work in neuroscience and public health to a global audience, with programming set to reach over 245 million homes weekly across the U.S. and Middle East.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036120) on June 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}